

B. Braun / Trendlines Partnership Leads to ApiFix Investment

Misgav, Israel; Tuttlingen, Germany – 28 November 2016 – [B. Braun Melsungen AG \(“B. Braun”\)](#), [The Trendlines Group Ltd. \(“Trendlines”\)](#) and [ApiFix Ltd. \(“ApiFix”\)](#) jointly announced B. Braun's lead position in ApiFix's B round financing; ApiFix is a Trendlines portfolio company. B. Braun's Aesculap division invested US\$2.8 million in the US\$5 million round which is to close by end of 2016.

ApiFix is disrupting the scoliosis device market with its minimally invasive, non-fusion spinal implant system for the correction of Adolescent Idiopathic Scoliosis (AIS). Traditional surgical correction is a highly invasive procedure involving fusion, which results in a rigid spine and low patient quality of life. The ApiFix system is implanted in a minimally invasive procedure and does not require fusion, thus maintaining spine flexibility and high quality of life. The global market for ApiFix is over US\$1.15 billion.¹ ApiFix received CE Mark in 2012 and is marketing its device in Europe. More than 100 operations have been performed with the ApiFix implant; first patients are now 4-years post-surgery. Clinical results and patient quality of life are excellent. ApiFix videos can be viewed at:

<https://www.youtube.com/watch?v=8Pn9dlrTMNA> and
<https://www.youtube.com/channel/UCvPLPheAOrplckoGviotA7w>.

ApiFix CEO, Eran Feldhay M.D., remarked: “Clinical experience with ApiFix's non-fusion correction system for the treatment of scoliosis is growing. We have now completed more than 100 surgeries with overwhelmingly positive results. This funding round will support our FDA submission in the coming months and assist the expansion of our clinical and commercial activities in Europe.”

ApiFix's founding investor and largest shareholder, Trendlines, welcomed B. Braun's investment. Todd Dollinger, Trendlines' Chairman and CEO, who also serves as chairman of ApiFix, said: “This round positions ApiFix for accelerated growth and brings B. Braun's substantial experience to ApiFix's board of directors. We look forward to B. Braun contributing to bringing ApiFix's breakthrough scoliosis solution – and future products – to patients around the world.”

B. Braun, one of the world's leading providers of healthcare solutions, began formal partnership activities with Trendlines in 2015, following collaboration that included the acquisition of the assets of one of Trendlines' portfolio companies. Trendlines and B. Braun have established mutual deal flow to identify potential new investment opportunities and are working together in the establishment of incubators and

¹ Provided by Life Science Intelligence (<http://lsintel.com/>) on global scoliosis market

collaboration in the development of new technologies, solutions, and products. B. Braun invested approximately US\$5 million in Trendlines as a cornerstone investor in Trendlines' 2015 initial public offering in Singapore. B. Braun and Trendlines have executed a memorandum of understanding for co-investment in Trendlines Medical Singapore, Trendlines' first incubator outside of Israel.

Prof. Dr. Hanns-Peter Knaebel, a member of the B. Braun Management Board and CEO of their Aesculap division, commented, "Our deep interest in innovation and in bringing disruptive products to patients and the medical community drives our internal R&D efforts and, as well, brings us to search the world for investment opportunities to achieve these same goals. Our investment in ApiFix, a Trendlines' portfolio company, further cements B. Braun and Trendlines collaboration effort."

About B. Braun

With over 56,000 employees in 64 countries, B. Braun is one of the world's leading manufacturers of medical devices and pharmaceutical products and services. Through constructive dialogue, B. Braun develops high quality product systems and services that are both evolving and progressive – and, in turn, improves people's health around the world. In 2015, the group generated sales of approximately €6.13 billion.

About The Trendlines Group Ltd.

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

*The Trendlines Group Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").*

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.